EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia

Medical Xpress

EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia

이 뉴스, 어떠셨어요?

한 번의 탭으로 반응을 남겨요 · 로그인 불필요

For patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), adding pirtobrutinib to venetoclax-rituximab (PVR) yields improved progression-free survival (PFS) compared to venetoclax-rituximab (VR), according to a study presented at the annual congress of the European Hematology Association, held from June 11 to 14 in Stockholm. ...

전문 보기

EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Zero-waste plastic and color recycling: The end of colored plastic downgrading could be near

Dual-mobility hip replacement implant can lower dislocation risk by 70%

Single ion maps 3D electromagnetic fields above chips with record sensitivity

Medical Xpress의 다른 기사

FDA approves Tzield for children with new stage 3 type 1 diabetes

Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM

New drug unlocks elusive immune receptor, opening path toward motor neuron disease treatments